Epstein Barr Virus News and Research

Latest Epstein Barr Virus News and Research

Canadian discovery could lead to development of vaccine against Epstein-Barr virus

Development of a vaccine against Epstein-Barr virus has taken a step forward with the Canadian discovery of how EBV infection evades detection by the immune system.

12 Oct 2013

Sahlgrenska Academy study finds no traces of viruses in breast cancer and glioblastoma

A major study conducted at the Sahlgrenska Academy has now disproved theories of a viral cause for breast cancer and the brain tumour, glioblastoma. The study, which was based on over seven billion DNA sequences and which is published in Nature Communications, found no genetic traces of viruses in these forms of cancer.

9 Oct 2013

Discovery paves way for development of new medicines to combat herpes infections

Researchers at Lund University in Sweden and Carnegie Mellon University have for the first time managed to measure the internal pressure that enables the herpes virus to infect cells in the human body. The discovery paves the way for the development of new medicines to combat viral infections. The results indicate good chances to stop herpes infections in the future.

3 Oct 2013

Resveratrol worsens MS-like neuropathology and inflammation, study finds

Resveratrol, a naturally occurring polyphenol compound produced by the skin of red grapes and peanuts, and found in red wine, has been touted as a beneficial supplement due to its anti-inflammatory and antioxidant properties.

1 Oct 2013

Study: Apoptosis triggers alternate replication pathway in HHV

Washington, DC-Researchers from Children's National Medical Center have found that an alternate, "escape" replication process triggered by apoptosis-the process of cell death or "cell suicide"-appears to be common in human herpesviruses (HHV).

28 Aug 2013

Epstein–Barr virus linked to improved gastric cancer survival

Research shows that Epstein–Barr virus positivity in gastric tumor cells is associated with improved prognosis.

25 Apr 2013

Horizon forms 3 new Centers of Excellence for gene editing in Asia

Horizon Discovery (Horizon), a leading provider of research tools to support the development of personalized medicines, today announced it has established three new Centers of Excellence (CoE's) for gene editing in Asia.

4 Mar 2013

Researchers identify second B-cell attachment receptor for Epstein-Barr virus

Epstein-Barr virus (EBV) affects more than 90 percent of the population worldwide and was the first human virus found to be associated with cancer. Now, researchers from Beth Israel Deaconess Medical Center (BIDMC) have broadened the understanding of this widespread infection with their discovery of a second B-cell attachment receptor for EBV.

21 Feb 2013

Tousled-like kinases play a key role in suppression and activation of herpesviruses

Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) hide within the worldwide human population. While dormant in the vast majority of those infected, these active herpesviruses can develop into several forms of cancer.

14 Feb 2013

Burkitt lymphoma risk after transplantation highlighted

Solid organ transplant recipients have a significant risk for developing Burkitt lymphoma (BL), US researchers have found.

12 Feb 2013

HDL cholesterol key to fighting lymphoma

High-density lipoprotein cholesterol could provide a novel treatment target for patients with lymphoma, US scientists believe.

25 Jan 2013

EBV reactivation can increase risk of heart disease

A new study could provide the link that scientists have been looking for to confirm that reactivation of a latent herpes virus is a cause of some heart problems.

23 Jan 2013

New study: Loneliness can harm overall health

New research links loneliness to a number of dysfunctional immune responses, suggesting that being lonely has the potential to harm overall health.

20 Jan 2013

Study finds important links between Pf malaria and endemic Burkitt Lymphoma

New research, presented this morning at the 54th Annual Meeting of the American Society of Hematology (ASH), has identified important associations between Plasmodium falciparum (Pf) malaria and endemic Burkitt Lymphoma (eBL) that may help researchers identify young children who are more susceptible to eBL.

12 Dec 2012

Potential diagnostic method to identify subset of patients with chronic fatigue syndrome

For the first time, researchers have landed on a potential diagnostic method to identify at least a subset of patients with chronic fatigue syndrome (CFS), a complex disorder with no known definitive cause or cure.

15 Nov 2012

Comparing animal and human cancer is of mutual benefit

A diagnosis of cancer once spelled the end for our animal companions but the launch today of a specialty cancer clinic, led by one of Australia’s leading veterinary oncologists at the University of Sydney, offers new hope.

14 Oct 2012

NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

Soligenix, Inc., a development stage biopharmaceutical company, announced today that the National Cancer Institute has awarded Soligenix a Small Business Innovation Research grant to support the conduct of a Phase 2 clinical trial designed to evaluate orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestation of chronic Graft-versus-Host disease.

5 Sep 2012

The Wistar Institute, MSKCC partner to publish first annotated atlas of Epstein-Barr virus genome

Researchers from The Wistar Institute and Memorial Sloan-Kettering Cancer Center (MSKCC) have teamed to publish the first annotated atlas of the Epstein-Barr virus genome, creating the most comprehensive study of how the viral genome interacts with its human host during a latent infection. Epstein-Barr virus (EBV), which is thought to be responsible for one percent of all human cancers, establishes a latent infection in nearly 100 percent of infected adult humans.

24 Aug 2012

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

BioDiem recently signed a collaborative agreement with The Royal Melbourne Institute of Technology (RMIT) for the development of non-influenza vaccines using BioDiem’s proprietary live attenuated influenza virus (LAIV) technology.

7 Aug 2012

BioDiem signs agreement with RMIT to create new non-influenza vaccines

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem’s live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem’s strategy, and this research is part of the work towards that goal.

19 Jul 2012

Epstein Barr Virus News and Research

Latest Epstein Barr Virus News and Research

Canadian discovery could lead to development of vaccine against Epstein-Barr virus

Sahlgrenska Academy study finds no traces of viruses in breast cancer and glioblastoma

Discovery paves way for development of new medicines to combat herpes infections

Resveratrol worsens MS-like neuropathology and inflammation, study finds

Study: Apoptosis triggers alternate replication pathway in HHV

Epstein–Barr virus linked to improved gastric cancer survival

Horizon forms 3 new Centers of Excellence for gene editing in Asia

Researchers identify second B-cell attachment receptor for Epstein-Barr virus

Tousled-like kinases play a key role in suppression and activation of herpesviruses

Burkitt lymphoma risk after transplantation highlighted

HDL cholesterol key to fighting lymphoma

EBV reactivation can increase risk of heart disease

New study: Loneliness can harm overall health

Study finds important links between Pf malaria and endemic Burkitt Lymphoma

Potential diagnostic method to identify subset of patients with chronic fatigue syndrome

Comparing animal and human cancer is of mutual benefit

NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

The Wistar Institute, MSKCC partner to publish first annotated atlas of Epstein-Barr virus genome

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

BioDiem signs agreement with RMIT to create new non-influenza vaccines

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Epstein Barr Virus News and Research

Latest Epstein Barr Virus News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in